Your selection basket is empty.
Define a selection of ETFs which you would like to compare.
Add an ETF by clicking "Compare" on an ETF profile or by checkmarking an ETF in the ETF search.
Summit Therapeutics
ISIN US86627T1088
|WKN A2QDFS
Market cap (in EUR)
11,696 m
Country
United States
Sector
Healthcare
Dividend yield
0.00%
Overview
Description
Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.
Healthcare Biopharmaceuticals Non-System-Specific Biopharmaceuticals United States
Financials
Key metrics
| Market capitalisation, EUR | 11,696 m |
| EPS, EUR | -1.38 |
| P/B ratio | 24.8 |
| P/E ratio | - |
| Dividend yield | 0.00% |
Income statement (2025)
| Revenue, EUR | - |
| Net income, EUR | -957 m |
| Profit margin | - |
What ETF is Summit Therapeutics in?
There are 12 ETFs which contain Summit Therapeutics. All of these ETFs are listed in the table below. The ETF with the largest weighting of Summit Therapeutics is the iShares Nasdaq US Biotechnology UCITS ETF USD (Dist).
Latest articles
— Data provided by Trackinsight, etfinfo, Xignite Inc., gettex, FactSet and justETF GmbH. Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.